Company: VREOF
Filing Date: 2025-05-09
Form Type: DEF 14A
Source: 0001140361-25-018064
Chunk: 53

Company: Vireo Growth Inc.
Filing Date: 2025-05-09
Form: DEF 14A
Chunk 53
---
 No. 1 to Schedule 13D filed with the SEC on April 22, 2025, on behalf of Chicago Atlantic Advisers, LLC (“CAA”), Chicago Atlantic Group GP, LLC (“CAGGP”), Chicago Atlantic Group, LP (“CAG”), Chicago Atlantic GP Holdings, LLC (“CAGPH”), Chicago Atlantic Manager, LLC (“CAM”), Chicago Atlantic Opportunity GP, LLC (“CAOGP”), and Chicago Atlantic Opportunity Portfolio, LP (“CAOP”). CAGGP is the general partner of CAG, which is the managing member of CAA, which is the investment manager of Chicago Atlantic Credit Opportunities, LLC (“CACO”) and CAOP. CAGPH is the managing member of CAM, which is the managing member of CACO. CAGPH is also the sole member of CAOGP which is the general partner of CAOP. The business address for the foregoing entities is 420 N Wabash Ave, Suite 500, Chicago, Illinois 60611. Additionally, this reflects 16,000,000 shares underlying convertible notes. On November 1, 2024, the Company entered into a joinder and tenth amendment to its existing senior secured delayed draw term loan granted pursuant to the credit agreement dated March 25, 2021, as amended, which provided a new convertible note facility with a maximum principal amount of $10 million. These convertible notes mature November 1, 2027, have a cash interest rate of 12.0% per year, are convertible into that number of the Company’s Subordinate Voting Shares determined by dividing the outstanding principal amount plus all accrued but unpaid interest on the convertible notes on the date of such conversion by a conversion price of $0.625 per share. This also reflects 6,091,179 currently exercisable warrants held collectively by the aforementioned entities. |

| (3) | Reflects 31,184,875 shares acquired by FarmaceuticalRX LLC in the equity raise completed by the Company in December 2024 on a private placement basis (the “Equity Raise”). |

| (4) | Includes 5,953,500 Options to purchase Subordinate Voting Shares that are exercisable within 60 days of April 22, 2025, and 262,708 RSUs that settle in Subordinate Voting Shares within 60 days of February 15, 2025. |

| (5) | Includes 2,619,453 Options to purchase Subordinate Voting Shares that are exercisable within 60